Background and objectives: Hematopoietic stem cell transplantation (HSCT) is potentially curative treatment for malignant and non-malignant diseases. Graft versus host disease (GVHD) remains a significant cause of morbidity and mortality following HSCT. An increased incidence of GVHD has been suggested following allogeneic peripheral blood stem cell transplantation (PBSCT), however, how this affects survival is not yet clear. In this study, our aim is to assess the impact of acute GVHD (aGVHD) on overall survival (OS) and progression free survival (PFS) following human leukocyte antigens (HLA) identical sibling PBSCT. Patients and methods: Data of 97 patients undergoing HLA identical sibling allogeneic PBSCT, were analyzed. We studied the incidence of aGVHD and their effects on survival. Survival analysis was done using Kaplan-Meier method to determine OS and PFS. Results: The overall incidence of aGVHD was 34%. The occurrence of grade 2-4 aGVHD was associated with decreased probability of PFS (P= 0.018). The development of grade 2-4 aGVHD was associated with lower OS compared with the absence of aGVHD (P= 0.021). Conclusion: These data indicate that the occurrence of aGVHD is an important factor that may influence the survival in HLA-identical sibling allogeneic PBSCT. Patients who developed aGVHD have a high chance of decreased probability of PFS and lower OS
(2016). Impact of acute graft versus host disease on survival after allogeneic peripheral blood stem cell transplantation. SECI Oncology Journal, 4(1), 15-20. doi: 10.21608/secioj.2016.5677
MLA
. "Impact of acute graft versus host disease on survival after allogeneic peripheral blood stem cell transplantation", SECI Oncology Journal, 4, 1, 2016, 15-20. doi: 10.21608/secioj.2016.5677
HARVARD
(2016). 'Impact of acute graft versus host disease on survival after allogeneic peripheral blood stem cell transplantation', SECI Oncology Journal, 4(1), pp. 15-20. doi: 10.21608/secioj.2016.5677
VANCOUVER
Impact of acute graft versus host disease on survival after allogeneic peripheral blood stem cell transplantation. SECI Oncology Journal, 2016; 4(1): 15-20. doi: 10.21608/secioj.2016.5677